查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081992

神經保護市場：2026-2032年全球市場預測（依產品類型、作用機制、適應症、通路和最終用戶分類）

Neuroprotection Market by Product Type, Mechanism Of Action, Indication, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，神經保護市場將成長至 587.4 億美元，複合年成長率為 7.93%。

主要市場統計數據
基準年 2025 344.2億美元
預計年份：2026年 370.1億美元
預測年份 2032 587.4億美元
複合年成長率 (%) 7.93%

神經保護市場簡介

隨著神經系統疾病日益加重醫療系統、生物製藥研發管線和長期照護預算的負擔，神經保護正從一個主要處於實驗階段的概念轉變為一項重要的策略性醫療重點。根據世界衛生組織（世衛組織）統計，全球有超過5,500萬人患有失智症，而中風仍是導致死亡和殘疾的主要原因之一。 2019年，全球有超過850萬人被診斷出患有帕金森氏症，另有約280萬人被診斷出患有多發性硬化症，凸顯了急性和慢性神經退化性疾病整體存在著巨大的未滿足需求。

神經保護領域的變革性變化

神經保護領域正在經歷一場變革，從強調廣泛神經保護作用的方法轉向基於作用機制特異性生物標記的療法。臨床研發日益關注發炎、興奮性毒性、氧化壓力壓力、蛋白質穩態、突觸彈性、血管損傷和粒線體功能障礙。這項轉變意義重大，因為過去的神經保護臨床試驗常常因患者族群異質性導致可測量的療效被稀釋、治療啟動延遲或終點指標敏感性不足等原因而失敗。

人工智慧的累積影響

人工智慧 (AI) 透過改善標靶發現、化合物篩檢、影像分析、臨床試驗設計和病患監測，正在加速神經保護研究。 AI 模型可以整合基因組學、蛋白質組學、電子健康記錄、神經影像學和數位表現型分析，以識別高風險族群和生物學定義的亞群。這在阿茲海默症、帕金森氏症、肌萎縮側索硬化症 (ALS)、中風、創傷性腦損傷和視網膜神經退化中尤其重要，因為這些疾病的異質性歷來限制了臨床試驗的成功。

神經保護市場的關鍵區域洞察

亞太地區是神經保護領域成長最快的地區之一，這主要得益於人口老化、中風治療的擴展以及中國、日本、韓國、印度和澳洲在神經科學領域的大量投資。日本的超老化社會推動了對失智症和帕金森氏症治療的需求，而中國龐大的市場規模則為獲得大規模患者群體和擴大臨床試驗能力提供了支持。在印度，中風、糖尿病相關血管風險和創傷負擔的增加，使得對經濟實惠的神經保護和復健策略的需求日益成長。

針對特定群體的關鍵洞察，以進行策略市場優先排序

在東協市場，由於醫院網路不斷擴張、非傳染性疾病盛行率上升以及神經科疾病診療服務可及性的提高，神經保護的需求日益成長；然而，治療費用和保險報銷差異仍然是主要阻礙因素。隨著海灣合作理事會（GCC）成員國加大對先進三級醫療、基因組學和數位醫療的投資，該地區有望採用高價值的神經系統診斷和專業的神經保護療法。

各國在神經保護方面的主要見解

由於美國國立衛生研究院 (NIH) 的大力資助、美國食品藥物管理局(FDA) 在神經退化性疾病治療方面的先例以及先進主導技術的高普及率，美國在神經保護研究的商業化方面處於領先地位。加拿大兼具公共醫療保健的便利性和強大的神經科學研究實力，而墨西哥和巴西是重要的拉丁美洲市場，其卒中治療不斷擴展，私營部門對神經病學的需求也不斷成長。英國、德國、法國、義大利和西班牙擁有完善的臨床研究和保險報銷審查機制，其中德國和法國尤其對衛生技術評估 (HTA) 和專科醫療路徑具有重要影響力。

為行業領導者提供的實用建議

產業領導者應優先考慮以生物標記主導的研發策略，在後期臨床試驗之前明確定義目標族群、作用機制和可衡量的神經保護效果。與學術神經科學中心、影像網路、臨床研究機構和患者登記機構建立合作關係，可以提高受試者招募品質並降低終點指標的不確定性。此外，針對監管機構、保險公司、醫生和看護者的證據材料包也必不可少，尤其是在治療費用昂貴、侵入性或需要長期監測的情況下。

調查方法

本調查方法基於二手資料研究，參考了檢驗的公共衛生、監管、臨床和科學資訊來源，包括世界衛生組織（WHO）、各國衛生機構、同行評審的神經科學文獻以及美國食品藥品監督管理局（FDA）和歐洲藥品管理局（EMA）等權威機構發布的監管資訊。分析評估了疾病負擔、臨床發展趨勢、技術應用、區域醫療保健系統以及影響神經保護市場的政策因素。

結論

神經保護正進入一個更系統化和商業性的重要階段，這主要得益於人口老化、生物標記的改進、先進的成像技術、人工智慧驅動的藥物研發以及對神經損傷機制更深入的理解。市場機會龐大，而成功取決於臨床針對性、證據品質以及能否證明神經功能得到可衡量的維持。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 神經保護市場：依產品類型分類

  • 生物製劑
    • 單株抗體生物製劑
    • 神經營養因子生物製劑
  • 製藥
    • 基於胜肽的藥物
    • 小分子藥物
  • 基因治療
  • 營養保健品
    • 草藥萃取物營養保健品
    • 礦物質和營養保健品
    • 維生素類營養保健品
  • 幹細胞療法

第8章：神經保護劑市場：依作用機制分類

  • 抗發炎藥
    • 細胞激素抑制劑和抗發炎藥物
    • 非類固醇抗發炎藥
    • 類固醇抗發炎藥
  • 抗氧化劑
    • 黃酮類抗氧化劑
    • 維生素C抗氧化劑
    • 維生素E抗氧化劑
  • 鈣離子通道阻斷劑
    • 離胺酸鈣離子通道阻斷劑
    • 尼莫地平鈣離子通道阻斷劑
  • 麩胺酸抑制劑
  • 神經營養因子
  • NMDA拮抗劑
    • 基於氯胺酮的NMDA拮抗劑
    • MemantineNMDA 受體拮抗劑

第9章：神經保護市場：依適應症分類

  • 阿茲海默症
    • 阿茲海默症早期
    • 中度阿茲海默症
    • 重度阿茲海默症
  • 多發性硬化症
    • 復發型多發性硬化症
    • 次發漸進型性多發性硬化症
  • 帕金森氏症
    • 姿勢不穩 帕金森氏症
    • 震顫型帕金森氏症
  • 脊髓損傷
  • 中風
    • 出血性中風
    • 缺血性中風
  • 創傷性腦損傷

第10章：神經保護市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章：神經保護市場：依最終用戶分類

  • 診所
  • 家庭醫療保健
  • 醫院
  • 研究機構

第12章：神經保護市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：神經保護市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 神經保護市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • AC Immune SA
  • AstraZeneca PLC
  • Bayer AG
  • BioArctic AB
  • Biogen Inc.
  • Bioniz Therapeutics Inc.
  • Boston Scientific Corporation
  • Denali Therapeutics Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Genervon Biopharmaceuticals, LLC
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Hikma Pharmaceuticals PLC
  • Ipsen SA
  • Johnson & Johnson
  • LivaNova PLC
  • Medtronic plc
  • Merck & Co., Inc.
  • Neuren Pharmaceuticals Limited
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Stryker Corporation
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
Product Code: MRR-430D42AA0F33

The Neuroprotection Market is projected to grow by USD 58.74 billion at a CAGR of 7.93% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 34.42 billion
Estimated Year [2026] USD 37.01 billion
Forecast Year [2032] USD 58.74 billion
CAGR (%) 7.93%

Neuroprotection Market Introduction

Neuroprotection is moving from a largely experimental concept to a strategic healthcare priority as neurological disorders place rising pressure on health systems, biopharmaceutical pipelines, and long-term care budgets. The World Health Organization reports that more than 55 million people live with dementia worldwide, while stroke remains a leading cause of death and disability. Parkinson's disease affected more than 8.5 million people in 2019, and multiple sclerosis affects an estimated 2.8 million people globally, reinforcing the scale of unmet need across acute and chronic neurodegenerative conditions.

The neuroprotection market includes disease-modifying drugs, biologics, cell and gene therapies, mitochondrial and anti-inflammatory approaches, digital biomarkers, neuromonitoring tools, and supportive technologies designed to preserve neuronal structure and function. Demand is strongest where aging populations, improved diagnostic capacity, stroke systems of care, and advanced neuroscience research converge. For industry leaders, the opportunity is no longer limited to symptom control; it is increasingly defined by measurable slowing of neuronal injury, earlier intervention, and evidence-based patient stratification.

Transformative Shifts in the Neuroprotection Landscape

The neuroprotection landscape is being reshaped by the shift from broad neuroprotective claims toward mechanism-specific, biomarker-guided therapies. Clinical development is increasingly focused on inflammation, excitotoxicity, oxidative stress, proteostasis, synaptic resilience, vascular injury, and mitochondrial dysfunction. This change is important because past neuroprotection trials frequently failed when heterogeneous patient populations, delayed treatment windows, or insensitive endpoints diluted measurable benefit.

Regulatory and clinical momentum is also changing expectations. The U.S. FDA's accelerated approval pathway for anti-amyloid therapies in Alzheimer's disease and subsequent confirmatory requirements have reinforced the role of biomarkers, real-world safety monitoring, and clinically meaningful outcomes. In stroke and traumatic brain injury, improved imaging, thrombectomy systems, and critical care protocols are creating more precise opportunities for adjunctive neuroprotective interventions. Across the sector, success increasingly depends on matching the right mechanism to the right patient at the right stage of neuronal injury.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating neuroprotection research by improving target discovery, compound screening, imaging analytics, trial design, and patient monitoring. AI models can integrate genomics, proteomics, electronic health records, neuroimaging, and digital phenotyping to identify high-risk populations and biologically defined subgroups. This is especially relevant in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke, traumatic brain injury, and retinal neurodegeneration, where disease heterogeneity has historically limited trial success.

The cumulative impact of AI is most visible in faster hypothesis generation and more efficient clinical development. Machine learning can detect subtle progression signals in MRI, PET, optical coherence tomography, speech, gait, and wearable sensor data, supporting earlier endpoint detection. However, industry adoption must be governed by explainability, bias mitigation, cybersecurity, validation across diverse populations, and compliance with evolving FDA, EMA, and data protection frameworks. AI will not replace clinical evidence, but it is becoming a critical infrastructure layer for precision neuroprotection.

Key Regional Insights Across Neuroprotection Markets

Asia-Pacific is one of the fastest-moving neuroprotection regions due to population aging, expanding stroke care, and high neuroscience investment in China, Japan, South Korea, India, and Australia. Japan's super-aged population strengthens demand for dementia and Parkinson's disease solutions, while China's scale supports large patient cohorts and expanding clinical trial capacity. India's burden of stroke, diabetes-related vascular risk, and traumatic injury is increasing the need for affordable neuroprotective and rehabilitation strategies.

North America remains a global leader in neuroprotection innovation, supported by NIH-funded neuroscience research, FDA regulatory pathways, advanced biomarker infrastructure, and deep clinical trial capacity. Europe benefits from strong public research networks, EMA oversight, rare disease and neuroscience programs, and coordinated health technology assessment, while Latin America shows growing demand linked to stroke, aging, and access expansion in Brazil and Mexico. The Middle East is investing in specialty hospitals, precision medicine, and tertiary neurology services, particularly in GCC markets, while Africa faces major access gaps but rising need due to stroke, infectious neurologic complications, epilepsy, and traumatic injury.

Key Group Insights for Strategic Market Prioritization

ASEAN markets are strengthening neuroprotection demand through expanding hospital networks, rising noncommunicable disease prevalence, and improving access to neurology services, although affordability and reimbursement variability remain key constraints. The GCC is investing in advanced tertiary care, genomics, and digital health, positioning the region for adoption of high-value neurodiagnostics and specialty neuroprotective therapies.

The European Union provides a structured environment for neuroscience research, clinical trials, pharmacovigilance, data protection, and health technology assessment, making evidence quality central to market access. BRICS countries combine large patient populations with expanding domestic manufacturing and clinical research capacity, creating scale opportunities for both innovative and cost-effective therapies. G7 markets remain the primary centers for premium neuroprotection innovation, regulatory science, advanced imaging, and specialist care, while NATO countries' interest in traumatic brain injury, blast exposure, and military neurology supports specialized research into acute neuroprotection and rehabilitation.

Key Country Insights in Neuroprotection

The United States leads in neuroprotection research commercialization, with strong NIH funding, FDA precedent in neurodegenerative therapies, and high adoption of advanced diagnostics. Canada combines public healthcare access with neuroscience research strength, while Mexico and Brazil represent important Latin American markets where stroke care expansion and private-sector neurology demand are growing. The United Kingdom, Germany, France, Italy, and Spain support robust clinical research and reimbursement scrutiny, with Germany and France especially influential in health technology assessment and specialist care pathways.

Russia maintains neuroscience capabilities but faces geopolitical and access constraints that affect international collaboration. China is rapidly scaling neurology research, domestic biopharma, and clinical trial enrollment, while India offers large unmet need and cost-sensitive opportunities in stroke, epilepsy-related injury, and neurodegeneration. Japan's aging population makes dementia and Parkinson's disease priorities, South Korea is strong in digital health and biotechnology, and Australia contributes high-quality clinical research, registries, and regional trial leadership.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker-led development strategies that define target populations, mechanism of action, and measurable neuroprotective outcomes before late-stage trials. Partnerships with academic neuroscience centers, imaging networks, clinical research organizations, and patient registries can improve recruitment quality and reduce endpoint uncertainty. Organizations should also design evidence packages that address regulators, payers, physicians, and caregivers, particularly where therapies are expensive, invasive, or require long-term monitoring.

Commercial leaders should segment opportunities by disease stage, care setting, and urgency of intervention. Acute indications such as stroke and traumatic brain injury require rapid administration models, emergency workflow alignment, and hospital protocol integration, while chronic diseases such as Alzheimer's and Parkinson's demand longitudinal evidence, adherence support, caregiver engagement, and safety monitoring. Scalable AI, real-world evidence, and decentralized assessment tools should be adopted, but only after validation in diverse populations and alignment with privacy and clinical governance standards.

Research Methodology

Research methodology is based on secondary research from verified public health, regulatory, clinical, and scientific sources, including the World Health Organization, national health agencies, peer-reviewed neuroscience literature, and publicly available regulatory information from authorities such as the FDA and EMA. The analysis evaluates disease burden, clinical development trends, technology adoption, regional healthcare capacity, and policy factors influencing the neuroprotection market.

The methodology emphasizes triangulation of evidence rather than reliance on single-source estimates. Insights are synthesized across epidemiology, clinical trial activity, biomarker adoption, reimbursement considerations, and healthcare infrastructure. Market interpretation excludes unsupported claims and focuses on data-backed drivers such as aging demographics, neurological disease prevalence, validated diagnostic advances, regulatory milestones, and documented artificial intelligence applications in neuroscience.

Conclusion

Neuroprotection is entering a more disciplined and commercially relevant phase, driven by aging populations, improved biomarkers, advanced imaging, AI-enabled discovery, and stronger understanding of neuronal injury mechanisms. The market opportunity is significant, but success will depend on clinical specificity, evidence quality, and the ability to demonstrate measurable preservation of neurological function.

Organizations that integrate precision medicine, regulatory-grade data, real-world monitoring, and region-specific access strategies will be best positioned to lead. As healthcare systems face growing neurological disease burden, neuroprotective therapies and technologies that deliver clinically meaningful outcomes can become central to the future of brain health, stroke recovery, and neurodegenerative disease management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Neuroprotection Market, by Product Type

  • 7.1. Biologics
    • 7.1.1. Monoclonal Antibody Biologics
    • 7.1.2. Neurotrophic Factor Biologics
  • 7.2. Drugs
    • 7.2.1. Peptide Drugs
    • 7.2.2. Small Molecule Drugs
  • 7.3. Gene Therapy
  • 7.4. Nutraceuticals
    • 7.4.1. Herbal Extract Nutraceuticals
    • 7.4.2. Mineral Nutraceuticals
    • 7.4.3. Vitamin Nutraceuticals
  • 7.5. Stem Cell Therapy

8. Neuroprotection Market, by Mechanism Of Action

  • 8.1. Anti Inflammatory Agents
    • 8.1.1. Cytokine Inhibitor Anti Inflammatory Agents
    • 8.1.2. NSAID Anti Inflammatory Agents
    • 8.1.3. Steroid Anti Inflammatory Agents
  • 8.2. Antioxidants
    • 8.2.1. Flavonoid Antioxidants
    • 8.2.2. Vitamin C Antioxidants
    • 8.2.3. Vitamin E Antioxidants
  • 8.3. Calcium Channel Blockers
    • 8.3.1. Flunarizine Calcium Channel Blockers
    • 8.3.2. Nimodipine Calcium Channel Blockers
  • 8.4. Glutamate Inhibitors
  • 8.5. Neurotrophic Factors
  • 8.6. NMDA Antagonists
    • 8.6.1. Ketamine NMDA Antagonists
    • 8.6.2. Memantine NMDA Antagonists

9. Neuroprotection Market, by Indication

  • 9.1. Alzheimer's Disease
    • 9.1.1. Early Stage Alzheimer's Disease
    • 9.1.2. Moderate Stage Alzheimer's Disease
    • 9.1.3. Severe Stage Alzheimer's Disease
  • 9.2. Multiple Sclerosis
    • 9.2.1. Relapsing Remitting Multiple Sclerosis
    • 9.2.2. Secondary Progressive Multiple Sclerosis
  • 9.3. Parkinson's Disease
    • 9.3.1. Postural Instability Parkinson's Disease
    • 9.3.2. Tremor Dominant Parkinson's Disease
  • 9.4. Spinal Cord Injury
  • 9.5. Stroke
    • 9.5.1. Hemorrhagic Stroke
    • 9.5.2. Ischemic Stroke
  • 9.6. Traumatic Brain Injury

10. Neuroprotection Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Neuroprotection Market, by End User

  • 11.1. Clinics
  • 11.2. Home Healthcare
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. Neuroprotection Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Neuroprotection Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neuroprotection Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. AbbVie Inc.
  • 16.3. AC Immune SA
  • 16.4. AstraZeneca PLC
  • 16.5. Bayer AG
  • 16.6. BioArctic AB
  • 16.7. Biogen Inc.
  • 16.8. Bioniz Therapeutics Inc.
  • 16.9. Boston Scientific Corporation
  • 16.10. Denali Therapeutics Inc.
  • 16.11. Eisai Co., Ltd.
  • 16.12. Eli Lilly and Company
  • 16.13. Genervon Biopharmaceuticals, LLC
  • 16.14. GlaxoSmithKline plc
  • 16.15. H. Lundbeck A/S
  • 16.16. Hikma Pharmaceuticals PLC
  • 16.17. Ipsen S.A.
  • 16.18. Johnson & Johnson
  • 16.19. LivaNova PLC
  • 16.20. Medtronic plc
  • 16.21. Merck & Co., Inc.
  • 16.22. Neuren Pharmaceuticals Limited
  • 16.23. Novartis AG
  • 16.24. Pfizer Inc.
  • 16.25. Roche Holding AG
  • 16.26. Sanofi S.A.
  • 16.27. Stryker Corporation
  • 16.28. Sun Pharmaceutical Industries Limited
  • 16.29. Teva Pharmaceutical Industries Ltd.
  • 16.30. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROPROTECTION MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL NEUROPROTECTION MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL NEUROPROTECTION MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL NEUROPROTECTION MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL NEUROPROTECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROPROTECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL NEUROPROTECTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NEUROPROTECTION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL NEUROPROTECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROPROTECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MONOCLONAL ANTIBODY BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MONOCLONAL ANTIBODY BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MONOCLONAL ANTIBODY BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROTROPHIC FACTOR BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEUROTROPHIC FACTOR BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROTROPHIC FACTOR BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEPTIDE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PEPTIDE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SMALL MOLECULE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUTRACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUTRACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUTRACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HERBAL EXTRACT NUTRACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HERBAL EXTRACT NUTRACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HERBAL EXTRACT NUTRACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MINERAL NUTRACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MINERAL NUTRACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MINERAL NUTRACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VITAMIN NUTRACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VITAMIN NUTRACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VITAMIN NUTRACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI INFLAMMATORY AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI INFLAMMATORY AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTI INFLAMMATORY AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NSAID ANTI INFLAMMATORY AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NSAID ANTI INFLAMMATORY AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NSAID ANTI INFLAMMATORY AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL STEROID ANTI INFLAMMATORY AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL STEROID ANTI INFLAMMATORY AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL STEROID ANTI INFLAMMATORY AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIOXIDANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIOXIDANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIOXIDANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FLAVONOID ANTIOXIDANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FLAVONOID ANTIOXIDANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FLAVONOID ANTIOXIDANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VITAMIN C ANTIOXIDANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VITAMIN C ANTIOXIDANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VITAMIN C ANTIOXIDANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VITAMIN E ANTIOXIDANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VITAMIN E ANTIOXIDANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VITAMIN E ANTIOXIDANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FLUNARIZINE CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL FLUNARIZINE CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FLUNARIZINE CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NIMODIPINE CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NIMODIPINE CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NIMODIPINE CALCIUM CHANNEL BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GLUTAMATE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GLUTAMATE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GLUTAMATE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEUROTROPHIC FACTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROTROPHIC FACTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEUROTROPHIC FACTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NMDA ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NMDA ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NMDA ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL KETAMINE NMDA ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL KETAMINE NMDA ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL KETAMINE NMDA ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MEMANTINE NMDA ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MEMANTINE NMDA ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MEMANTINE NMDA ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL EARLY STAGE ALZHEIMER'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL EARLY STAGE ALZHEIMER'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL EARLY STAGE ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MODERATE STAGE ALZHEIMER'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MODERATE STAGE ALZHEIMER'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MODERATE STAGE ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SEVERE STAGE ALZHEIMER'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SEVERE STAGE ALZHEIMER'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SEVERE STAGE ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL RELAPSING REMITTING MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL RELAPSING REMITTING MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL RELAPSING REMITTING MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL POSTURAL INSTABILITY PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL POSTURAL INSTABILITY PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL POSTURAL INSTABILITY PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL TREMOR DOMINANT PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL TREMOR DOMINANT PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL TREMOR DOMINANT PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL SPINAL CORD INJURY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL SPINAL CORD INJURY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL SPINAL CORD INJURY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL STROKE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL STROKE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL STROKE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HEMORRHAGIC STROKE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL HEMORRHAGIC STROKE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL HEMORRHAGIC STROKE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ISCHEMIC STROKE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ISCHEMIC STROKE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ISCHEMIC STROKE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL TRAUMATIC BRAIN INJURY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL TRAUMATIC BRAIN INJURY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL TRAUMATIC BRAIN INJURY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA NEUROPROTECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA NEUROPROTECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE NEUROPROTECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST NEUROPROTECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA NEUROPROTECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. GLOBAL NEUROPROTECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN NEUROPROTECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. GCC NEUROPROTECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. GCC NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. GCC NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 281. GCC NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 282. GCC NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 283. GCC NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 284. GCC NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 285. GCC NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
  • TABLE 286. GCC NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 287. GCC NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 288. GCC NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 289. GCC NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 290. GCC NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 291. GCC NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 292. GCC NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 293. GCC NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 294. GCC NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS NEUROPROTECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 329. G7 NEUROPROTECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 330. G7 NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. G7 NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 332. G7 NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 333. G7 NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 334. G7 NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 335. G7 NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 336. G7 NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
  • TABLE 337. G7 NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 338. G7 NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 339. G7 NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 340. G7 NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 341. G7 NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 342. G7 NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 343. G7 NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 344. G7 NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 345. G7 NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 346. NATO NEUROPROTECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 347. NATO NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 348. NATO NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 349. NATO NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 350. NATO NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 351. NATO NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 352. NATO NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 353. NATO NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2032 (USD MILLION)
  • TABLE 354. NATO NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 355. NATO NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 356. NATO NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 357. NATO NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 358. NATO NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 359. NATO NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2032 (USD MILLION)
  • TABLE 360. NATO NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 361. NATO NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 362. NATO NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 363. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 364. UNITED STATES NEUROPROTECTION MARKET SIZE, 2018-2032 (